Anti-bcma chimeric antigen receptors
AssigneeCartesian Therapeutics, Inc.
InventorsYi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
Claims133
A chimeric antigen receptor (CAR) comprising:
- (i) an anti-B-Cell Maturation Antigen (BCMA) binding domain;
- (ii) a transmembrane domain;
- and
- (iii) a cytoplasmic domain,
- wherein the anti-BCMA binding domain comprises the amino acid sequence of any one of SEQ ID NOs:
- 1-18.
The method of any one of claims 99-115, further comprising administering an agent selected from the group consisting of:
- (i) an agent that increases the efficacy of the cell(s);
- (ii) an agent that ameliorates one or more side effects associated with administration of the cell(s);
- (iii) an agent that treats the cancer;
- and
- (iv) a combination of two or three of the agents.
The use of any one of claims 125-138, wherein the autoimmune disease is selected from the group consisting of myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, inflammatory bowel disease, celiac sprue, pernicious anemia, idiopathic thrombocytopenia purpura, sceleroderma, Graves disease, Sjögren syndrome, Goodpasture syndrome, and type 1 diabetes.
Dependencies are inferred from the claim text.